Gliatech other research news

GLIA received a $100,000 Phase I SBIR grant from the National Institute of Neurological Disorders and Stroke (NINDS) to further develop agents to stimulate the histamine H3 receptor. GLIA initially will focus on treatments for anxiety and insomnia.

H3 is a brain receptor that regulates release of histamine, aids in regulation of sleep/wake states, and modulates levels of arousal and alertness. ...